We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
An in-depth guide to Tarceva (erlotinib), a targeted therapy for specific lung and pancreatic cancers, covering its uses, dosage, side effects, and precautions for patients in India.
Tarceva, with its active ingredient erlotinib, is a targeted therapy medication used in the treatment of specific types of cancer. In India, like in many parts of the world, Tarceva has been a significant option for patients battling certain forms of lung and pancreatic cancer. This article provides a detailed overview of Tarceva, its uses, dosage, potential side effects, and important considerations for Indian patients.
Tarceva belongs to a class of drugs known as kinase inhibitors. It is a targeted therapy, meaning it specifically targets cancer cells by interfering with their growth and spread. Erlotinib, the active component of Tarceva, works by blocking the activity of a protein called the epidermal growth factor receptor (EGFR). Many cancer cells, particularly certain types of non-small cell lung cancer (NSCLC) and pancreatic cancer, rely on EGFR for their growth and survival. By inhibiting EGFR, Tarceva helps to slow down or stop the growth of these cancer cells.
Tarceva is primarily prescribed for adults diagnosed with specific types of cancer. In India, its approved uses include:
It is crucial to note that Tarceva is only effective for NSCLC if the cancer cells possess specific EGFR mutations. Your doctor will conduct tests to confirm the presence of these mutations before prescribing Tarceva.
The dosage of Tarceva is determined by your doctor based on your specific condition, cancer type, and overall health. The medication comes in tablet form and is usually taken once daily. Common strengths available are 25 mg, 100 mg, and 150 mg.
Important Administration Instructions:
Like all medications, Tarceva can cause side effects. While not everyone experiences them, it's important to be aware of the possibilities. Side effects can range from mild to serious.
Your doctor can often help manage these mild side effects. For instance, anti-diarrheal medications or skin care routines may be recommended.
While less common, serious side effects can occur. It is vital to contact your doctor immediately if you experience any of the following:
If you suspect a medical emergency, call emergency services (like 108 or 112 in India) immediately.
Several precautions are necessary when taking Tarceva:
The diagnosis of the cancers treated by Tarceva involves various methods, including imaging tests (like CT scans, PET scans) and biopsies. Crucially, a test to identify specific EGFR mutations in tumor cells is required before Tarceva can be prescribed for NSCLC. During treatment, your doctor will monitor your response to the medication and check for side effects through regular blood tests and clinical evaluations.
You should consult your doctor immediately if you experience any severe side effects. Additionally, seek medical advice if:
While Tarceva is a treatment for existing cancer, adopting a healthy lifestyle can support overall well-being during treatment. This includes:
Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026

Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026